Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allo-HSCT for Patients With FLT3-ITD AML

CompletedOBSERVATIONAL
Enrollment

456

Participants

Timeline

Start Date

January 1, 2012

Primary Completion Date

July 21, 2018

Study Completion Date

December 31, 2020

Conditions
Acute Myeloid LeukemiaAcute Myeloid Leukemia With FLT3/ITD MutationHematopoietic Stem Cell Transplantation
Interventions
DRUG

Sorafenib

The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).

Trial Locations (1)

510515

Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou

All Listed Sponsors
collaborator

Peking University People's Hospital

OTHER

collaborator

Third Affiliated Hospital, Sun Yat-Sen University

OTHER

collaborator

Zhujiang Hospital

OTHER

collaborator

Xiangya Hospital of Central South University

OTHER

collaborator

First People's Hospital of Chenzhou

OTHER

collaborator

The First Affiliated Hospital of Guangzhou Medical University

OTHER

collaborator

Institute of Hematology & Blood Diseases Hospital, China

OTHER

collaborator

The First Affiliated Hospital of Soochow University

OTHER

collaborator

Xinqiao Hospital of Chongqing

OTHER

collaborator

First Affiliated Hospital of Zhejiang University

OTHER

lead

Nanfang Hospital, Southern Medical University

OTHER

NCT04788420 - Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allo-HSCT for Patients With FLT3-ITD AML | Biotech Hunter | Biotech Hunter